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Summary We have investigated whether an alternating induction chemotherapy regimen of PVB/BEP is 
superior to BEP in patients with poor-prognosis testicular non-seminoma. A total o f 234 eligible patients were 
randomised to receive an alternating schedule o f  PVB/BEP for a total of four cycles or four cycles of BEP. 
Poor prognosis was defined as any of the following: lymph node metastases larger than 5 cm, lung metastases 
more than four in number or larger than 2 cm, haematogenic spread outside the lungs, such as in liver and 
bone, human chorionic gonadotrophin>  10 000 I U 1 -1 or alphafetoprotein> 1000 IU I" 1. The complete 
response (CR) rates to PVB/BEP and BEP were similar, 76% and 72% respectively (P — 0.58). In addition, 
there was no significant difference in relapse rate, disease-free and overall survival at an average follow-up o f  6 
years. The 5-year progression-free and survival rates in both treatment groups were approximatley 80%. The 
PVB/BEP regime was more toxic with regard to bone marrow function; the frequencies o f  leucocytes below 
1000 fil-1, leucocytopenic fever and platelets below 25 000 fit-1, throughout four cycles were 28% vs 5% 
(ƒ* <  0.001), 16% vs 5% {P — 0.006), and 10% v.v 1% (P =  0.001) respectively. Neuropathy also occurred more 
often in the PVB/BEP arm: 47% v.v 25% (P =  0.001). This study shows that an alternating regimen o f  
PVB/BEP is not superior to BEP and that it is more myelo- and neurotoxic.
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Cisplatin combination chemotherapy has increased the long- Therefore, the Genitourinary Group of the European
term survival rates o f patients with disseminated testicular Organization for Research and Treatment o f  Cancer 
non-seminoma from 10% to approximately 70% (Einhora, (EORTC) decided to perform a randomised study of four
1981; Stoter et al., 1989). Variables associated with a poor cycles of induction chemotherapy comparing BEP as the
prognosis include extent of metastases and serum levels o f  standard regimen with alternating cycles of PVB and BEP in
^-subunit o f human chorionic gonadotrophin (HCG) above 
10 000 IU  1 ~ 1 and/or alphafetoproteifi (AFP) above 1000 
IU l _l (Medical Research Council, 1985; Bosl et a l 1983;
poor-prognosis patients. The definition o f poor prognosis
from the preceding EORTC .study in whichwas
PBV-treated patients with lymph node metastases >  5 cm or
Birch et al., 1986; Stoter et al., 1987). Several studies have lung metastases > 2  cm achieved a CR rate o f only 56% as 
shown that complete (CR) rates fall by 30-50%  in the compared with 88% in patients with less extensive metastases
presence o f one or more poor-prognosis factors (Bajorin et 
al., 1988; Mead et al., 1992).
Etoposide has been shown to be active against cisplatin- 
resistant germ cell tumours, indicating non-cross-resistance 
(Williams et al., 1980; Bosl et al., 1985). Moreover, the 
combination o f  cisplatin, etoposide and bleomycin (BEP) has 
greater anti-tumour activity in poor-prognosis patients than 
the combination o f  cisplatin, vinblastine and bleomycin 
(PVB) (Williams et al., 1987). To improve the results o f  
induction chemotherapy in patients with poor-prognosis 
criteria, both the introduction of new active agents and the 
concept of alternating chemotherapy combinations could be 
exploited (Goldie et al., 1982; Goldie and Goldman, 1984).
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(Stoter et al., 1986).
Materials and methods
Patients were eligible for the study if they had metastatic 
testicular non-seminoma with any of the following charac­
teristics: lymph node metastases > 5  cm, lung metastases 
> 4  in number or > 2  cm, haematogenic spread outside the 
lungs such as in liver or bone, H C G >  10000 IU I"1 or AFP  
>  1000 IU l" 1. These cut-off levels o f  serum markers were 
based on prognostic factors analyses of EORTC (Stoter et 
al., 1986) and MRC (Medical Research Council, 1985). 
Patients were not accepted for the study if they had pure 
seminoma in the primary tumour, brain metastases, prior 
radiotherapy or chemotherapy, white blood count (WBC) 
below 2000 jtxl~*, platelet count below 100 000 fil-1 or a 
creatinine clearance below 40 ml min“1.
Patients were randomised to receive four cycles o f BEP or 
alternating treatment cycles with PVB/BEP/PVB/BEP. BEP 
consisted of cisplatin 20 m gm "2 intravenously (i.v.) on days 
1 - 5  every 3 weeks; etoposide, 120 m g m ”2 i.v. on days 1,3 
and 5 every 3 weeks; and bleomycin 30 mg i.v. on day 2, 
weekly for 12 weeks. For PVB the schedule was the same as 
for cisplatin and bleomycin, with vinblastine 0.15 mg kg-1 
i.v. on days 1 and 2 every 3 weeks. If at the start o f a
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treatment cycle the WBC was below 1500jul 1 or platelets 
below 50 000 jul~1, treatment was delayed for 1 week. If after
1 week the WBC was not above 3000 |iil 
above 100 000 ul“ 1,
-I and platelets
dose modifications of etoposide and 
vinblastine wrere applied. Cisplatin and bleomycin were with­
held if creatinine clearance fell below 40 m lm in -1. If renal 
function recovered, cisplatin and bleomycin were resumed at 
75% and 100% respectively. Severe skin toxicity and signs o f  
lung toxicity were reasons for termination o f bleomycin.
After four cycles, patients with normal levels of tumour
treatment failures, the CR rates were again not statistically
different: 64% on BEP and 67% on PVB/BEP (7> =  0.65).
After an average follow-up of 6 years (maximum 10 years) 
the relapse rates from CR were 16% on BEP and 12% on
PVB/BEP (P =  0.50).
Time to progression and survival
There were no significant differences in time to progression 
{P =  0.27) or duration o f survival (P — 0.32) between the
markers and no clinical or roentgenographic evidence o f  treatment groups. Figure 1 gives the duration o f  survival by
residual masses were classified as complete responders and 
were followed without further therapy. Patients in whom
treatment group for all 234 eligible patients. The 5 year 
progression-free and survival rates in both treatment groups
markers were normalised but who showed evidence o f are approximately 80%. When the log-rank survival analysis
residual tumour mass underwent debulking surgery. They 
were classified as complete responders if histological 
examination showed no viable cancer cells. Patients who still 
had elevated tumour markers after four cycles and those with 
viable cancer in the resected specimens were classified as 
treatment failures.
Rising tumour markers or an increase in tumour volume 
was considered as an end point indicating progression o f  
disease. Response rates to the treatment regimens were com­
pared by using the standard chi-square test for contingency 
tables. For comparison of toxicity, a chi-square test for linear 
trend was used. Time to progression and duration of survival 
curves were computed using the Kaplan-Meier product limit 
method and were compared using the log-rank test (Breslow, 
1984). The percentage of patients for whom follow-up was 
available after 5 years was decreased owing to the policy o f  
several institutions to dismiss patients after 5 years. Informed 
consent was obtained from all patients.
is restricted to the group of complete responders, the 5 year 
survival is 92%. Nine complete responders have died on BEP 
and six on PVB/BEP, thus there is again no 
difference between the two groups (P =  0.41).
A total of 138 (67%) of the 204 fully evaluable patients 
underwent explorative surgery to assess the response to treat­
ment. Twenty-four (17%) still had viable cancer cells, that is 
14 (20%) of 71 patients on BEP and 10 (15%) o f  67 patients 
on PVB/BEP. In 61 patients (44%), the resected specimen 
showed mature teratoma. The remaining 53 patients had 
fibronecrotic remnants or normal architecture. Eight (33%) 
of the patients with residual cancer and eight (13%) of the 
patients with mature teratoma relapsed and died of cancer.
Results
Between March 1983 and August 1987, 250 patients were 
entered, of whom 125 were randomised to BEP and 125 to 
PVB/BEP. Sixteen patients (seven on BEP and nine on PVB/
Toxicityw
The haematological toxicity throughout four cycles in the 234 
eligible patients is presented in Table II. The frequencies of 
leucocytes below 1 000 |xl~1 (28% v.v 5%), leucocytopenic 
fever (16% v.v 5%) and platelets below 25 000^1"' (10% v.v 
1%) are all significantly higher on the PVB/BEP arm.
Table III presents the non-hematological toxicity. Nausea, 
vomiting, paraesthesia, skin reactions and mucositis were theBEP) were ineligible, predominantly because of histology 
other than non-seminoma. Out o f the 234 eligible patients, 26 most frequent side-effects. Neuropathy occurred significantly
(13 on each treatment) were not evaluable for response, 
predominantly as a result o f  omitted explorative surgery. 
However, all 234 eligible patients were included in the time to 
progression and the survival analysis. Two patients on the 
BEP arm died of malignant disease before the completion o f  
chemotherapy. On the PVB/BEP arm two patients died of  
treatment related toxicity. These four patients were con­
sidered treatment failures.
more frequently in the PVB/BEP arm: 47% v.v 25% 
{P — 0.001). As a result of toxicity, chemotherapy dosages 
were reduced in 60% of patients on PVB/BEP and in 68% of
Table I Response to treatment
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Patient characteristics
Patient characteristics in the 234 eligible patients were well 
balanced between two treatment groups, except that 
trophoblastic tumour elements were diagnosed in 20% of the 
primaries in the patients on BEP compared with 13% on the 
PVB/BEP arm. Sixty-five per cent o f  patients had retro­
peritoneal lymph node metastases > 5  cm, 18% had media­
stinal and 16% had supraclavicular metastases. Forty- five 
percent of the patients had > 4  lung metastases and 31% 
had lung metastases, >  2 cm. Liver and bone metastases were 
present in 6% and 1% of the patients respectively.
ginie 
I ne valua hie 
Early death 
CR/eligible 
CR/evaluable
118
13
2
76 (64%) 
76 (72%)
PV B ! B E P
116 
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78 (76%)
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0.65
0.58
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According to currently poor prognosis criteria
vO0s*
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(Birch et ul., 1986; Stoter et al., 1990; Mead et al., 1992), 
17% of patients had abdominal masses > 1 0  cm and 14% 
had 20 or more lung metastases. Nine percent of patients 
had an HCG ^  10 000 IU I“ 1 and 23% had an AFP ^  1000 
IU l “ 1.
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Response to treatment
A total o f  105 patients on BEP and 103 patients on PVB/
BEP were evaluable for response. The CR were similar: 72% 
and 76%, respectively (P =  0.58) (Table I). When the 
inevaluable patients are included in the response analysis as Figure 1 Duration of survival.
0 2 4 6 8
Years
Number of patients at risk:
118 97 81 60 27
116 99 81 55 20
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BEP
PVB/BEP
B E P  vs P V B /B EP  In poor-risk non-semfnoma
R de Wit et al
1313
T a b l e  I I  Haematological toxicity
Side-effects BEP PVB/BEP p-value
Leucocytes <  1 000 fd ~1 6/118 (5%) 32/116 (28% ) < 0 .0 0 1
(W H O  grade 4)
Leucocytopenic fever 6/118 (5% ) 19/116 (16% ) 0.006
(leucocytes <  2 000 fxl - 1
T >  38°C)
Platelets < 2 5  000 /¿I“ 1 1/118 (1%) 12/116 (10% ) 0.001
(W H O  grade 4)
Table III N on-haem ato log ica l toxicity
BEP PVB! BEP p- value
Renal (creatinine 3/118 (3% ) 3/116 (3% )
>  1.25 N )
Allergic reactions 6/118 (5% ) 6/116 (5% )
G astro in testinal 112 /118(97% ) 1 14/116 (98% )
N europa thy 29/118 (25%) 54/116 (47% ) <0.001
M ucosal 19/118 (16%) 32/116 (28% ) <  0.05
Skin 56/118 (47% ) 50/116 (43 % )
Pulm onary  (fibrosis) 4/118 (3% ) 3/116 (3% )
patients on BEP. Chemotherapy was postponed in 24% of 
patients on PVB/PEB and in 20% of patients on BEP.
Discussion
The rationale for alternating administration of different 
chemotherapy combinations is based on the assumption that 
a tumour contains cell populations that are sensitive to one 
drug but resistant to another agent. Such heterogeneity may 
either exist at the initiation o f cytostatic treatment or develop 
during treatment as a result of biochemical modulation or 
genetic mutation (Goldie et al., 1982; Goldie and Goldman, 
1984). In the case of germ cell cancer it is likely that natural 
resistance is involved since these tumours proliferate rapidly 
and the duration of induction chemotherapy is restricted to 3 
or 4 months. These considerations favour the approach with 
alternating chemotherapy as the initial treatment in patients 
with poor-prognosis germ cell tumours.
This randomised study comparing four cycles of BEP with 
an alternating regimen of PVB/BEP for a total of four cycles 
in poor-prognosis patients shows no differences in CR rates, 
time-to progression and survival. PVB/BEP proved to be 
considerably more toxic with regard to bone marrow sup­
pression, leucocytopenic fever and neuromuscular symptoms.
It is concluded that the alternating regimen of PVB/BEP
does not yield better treatment results than BEP, but is 
accompanied by more toxicity. This is in agreement with the 
results of a phase II study of EP/VAB-6 at Memorial Sloan 
Kettering Cancer Center, which yielded a relapse-free sur­
vival rate of 37% in a group of patients for whom a relapse- 
free survival rate <50%  was predicted (Bosl et al., 1987), 
but is in contrast to the results of two single-institution phase 
II studies including the POMB/ACE regimen at the Charing 
Cross Hospital (Cullen et al., 1988; Hitchins et al., 1989) and
the CISCA/VB at the M.D, Anderson Hospital
(Logothetis et al., 1986), with which survival rates o f 70*-85%
have in poor-prognosis
bulky abdominal, mediastinal or pulmonary disease, or the 
presence of liver, bone or brain metastases. It is difficult to
the relative merits of these alternating regimens as the 
were not randomised and different prognostic selec­
tion criteria were used. The study here reported is the first 
testicular cancer trial which investigated the concept of alter­
nating chemotherapy in a randomised fashion. Of note, the 
standard arm in this study comprised BEP rather than PVB 
to avoid the possibility that an eventual treatment advantage 
of PVB/BEP could be due to the addition o f etoposide 
(Williams et al., 1987; Ozols et a i,  1988). The explanation for 
a lack of benefit of PVB/BEP over BEP may be mainly that 
cisplatin resistance is the crucial factor for treatment failure 
in testicular cancer. Since vinblastine and etoposide are not 
cross-resistant, the alternation of these drugs may not be an 
adequate method to test the concept o f  cross-resistance (Pas- 
tan and Gottesman, 1987). Other agents with significant 
activity in refractory disease such as ifosfamide (Loehrer et 
al., 1989, 1993; Motzer et al., 1992), and in particular the 
taxanes (Hutter et al., 1994), are new candidates for alter­
nating drug combinations which may merit further testing. In 
addition to the testing of alternating chemotherapy, short 
intervals between courses may also be further investigated. 
Data from the Royal Marsden Hospital suggest that the dose 
intensity of cisplatin at the beginning of the treatment may 
be important (Horwich et al., 1989). The design o f BOP/BEP 
involved four cycles of bleomycin, vincristine and cisplatin 
given over the initial 4 weeks, followed by three courses o f  
BEP at conventional 3 week intervals, yielding an 85% per- 
sistingly disease-free survival rate in with poor-
prognosis disease, defined by large volume disease and/or
bone or brain metastasis. This study was followed by
the testing of three BOP cycles, followed by three VIP cycles 
(Lewis et al., 1991), and this design has recently been inves-
in atigi
laborative trial comparing 
therapy’ using BEP, The results of this trial are awaited.
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